SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 17, 2022
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments	$ 17,625,620	$ 5,622,547
Unrealized gain	1,200,000
Impairment recognized	0	0
Royalty monetization liability	$ 30,000,000	0
Estimated useful life (in years)	3 years
Defined contribution plan name	401(k)-retirement plan
Contribution amount to retirement plan	$ 311,640	339,405
Pension Plan, Matching Scenario One
Summary of Significant Accounting Policy [Line Items]
Percentage of matching contribution from employer	100.00%
Percentage of eligible employees' contribution	3.00%
Pension Plan, Matching Scenario Two
Summary of Significant Accounting Policy [Line Items]
Percentage of matching contribution from employer	50.00%
Pension Plan, Matching Scenario Two | Minimum
Summary of Significant Accounting Policy [Line Items]
Percentage of eligible employees' contribution	3.00%
Pension Plan, Matching Scenario Two | Maximum
Summary of Significant Accounting Policy [Line Items]
Percentage of eligible employees' contribution	5.00%
Fair Value, Level 3
Summary of Significant Accounting Policy [Line Items]
Fair value assets	$ 0	0
Fair value liabilities	0	0
Money Market Funds and Short-term Investments | Fair Value, Level 1
Summary of Significant Accounting Policy [Line Items]
Fair value assets	25,700,000	42,500,000
Money Market Funds and Short-term Investments | Fair Value, Level 2
Summary of Significant Accounting Policy [Line Items]
Fair value assets	78,800,000	84,100,000
Promissory Notes
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments			$ 1,000,000
Interest rate, stated percentage			1.50%
Marinus Therapeutics Inc
Summary of Significant Accounting Policy [Line Items]
Equity method investments	1,300,000	500,000
Gensaic, Inc
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments	5,100,000	$ 5,100,000
Graviton Bioscience Corporation
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments	$ 11,200,000
Ligand Pharmaceuticals Incorporated | Purchase Agreement
Summary of Significant Accounting Policy [Line Items]
Commercial interest rate	13.00%
Ownership interest rate	100.00%